India markets closed

Biocon Limited (BIOCON.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
403.60+0.40 (+0.10%)
At close: 3:29PM IST
Full screen
Previous close403.20
Open404.30
Bid0.00 x 0
Ask0.00 x 0
Day's range398.10 - 408.60
52-week range235.55 - 478.00
Volume3,090,671
Avg. volume5,091,543
Market cap484.32B
Beta (5Y monthly)0.55
PE ratio (TTM)74.73
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date18-Jul-2019
1y target estN/A
  • Biocon secures approval to use drug on coronavirus patients
    Reuters

    Biocon secures approval to use drug on coronavirus patients

    India's Biocon Ltd has received regulatory approval for its drug Itolizumab to be used on coronavirus infected patients suffering from moderate to severe respiratory distress, the biopharmaceutical company said in a statement on Saturday. The drug, which is also used to cure the skin disease psoriasis, was cleared by the Drug Controller General of India (DCGI) for usage in India. "The randomised control trial indicated that all the patients treated with Itolizumab responded positively and recovered," said Kiran Mazumdar-Shaw, the firm's executive chairperson.

  • Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus
    Motley Fool

    Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus

    Here's some welcome news for diabetics dealing with the high price of insulin: The Food and Drug Administration has approved Mylan (NASDAQ: MYL) and Biocon's Semglee, which is essentially identical to Sanofi's (NASDAQ: SNY) insulin product Lantus. The companies didn't disclose what they plan to charge for Semglee when announcing the approval, but Mylan CEO Heather Bresch implied that it would be cheaper than Lantus. The opportunity for Mylan and Biocon (which bills itself as India's largest biopharmaceutical) is substantial; IQVIA estimates that Sanofi took in $1.68 billion in revenue from Lantus vials and $4.33 billion from the Lantus SoloSTAR Pen in the 12-month period that ended in April.

  • Sensex, Nifty hit four-month low as virus outbreak fans pandemic fears
    Reuters

    Sensex, Nifty hit four-month low as virus outbreak fans pandemic fears

    Indian stocks ended lower for a fifth straight day on Thursday after hitting four-month lows, as fears of the coronavirus becoming a pandemic made investors flee riskier assets. The broader NSE Nifty 50 index fell 0.4% to 11,633.30, while the benchmark S&P BSE Sensex declined 0.4% to 39,732.93. Governments ramped up measures on Thursday to battle a looming global pandemic of the coronavirus as the number of infections outside China, the source of the outbreak, for the first time surpassed those appearing inside the country.